"The future looks bright as far as a cure," one top HIV cure researcher told LGBTQ Nation.

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...

So far, there is no "magic bullet" to cure HIV for good, but scientists are making rapid progress.

Advancements in HIV/AIDS research, drug development, and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check ...

Gilead Sciences (NasdaqGS:GILD) plans to present late breaking data at CROI 2026 on a new investigational single tablet HIV regimen. The company will also share the first HIV cure clinical program ...

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS ...

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...